

CLAIMS

1. An imaging or contrast agent comprising a stereoisomer of a compound with at least one chiral centre, wherein said stereoisomer is in stereoisomeric excess and causes fewer adverse side effects on administration, or is less chemotoxic, than at least one other stereoisomer of said chiral compound.
2. An imaging or contrast agent as claimed in claim 1, comprising a stereoisomeric excess of a single stereoisomer, wherein said single stereoisomer causes fewer adverse side effects, or is less chemotoxic, than at least one other stereoisomer of the chiral compound.
3. An imaging or contrast agent as claimed in claim 2, wherein said single stereoisomer causes the fewest adverse side effects, or is the least chemotoxic, of said chiral compound's stereoisomers.
4. An imaging or contrast agent as claimed in any of the preceding claims, wherein the stereoisomer in stereoisomeric excess has a lower affinity for a human receptor than at least one other stereoisomer of said chiral compound.
5. An imaging or contrast agent as claimed in claim 4, wherein said stereoisomer in stereoisomeric excess has the lowest affinity for a human receptor of the chiral compound's stereoisomers.
6. An imaging or contrast agent as claimed in any of the preceding claims comprising greater than 50% of a single stereoisomer.
7. An imaging or contrasting agent as claimed in claim 6, wherein greater than 70, 75, 80, 85, 90, 95 or 98% of said compound is in the form of a single stereoisomer.

- 7 -

8. An imaging or contrast agent as claimed in any of the preceding claims and comprising a derivative of 2,4,6-triiodoisophthalic acid.

9. An imaging or contrast agent as claimed in claim 8, comprising a 2,4,6-triiodo-1-3-benzene dicarboxamide derivative with an R configured carbon located in an amido group bound to the 5 position in the benzene ring.

10. An imaging or contrast agent as claimed in claim 9, wherein the amido nitrogen is bound directly to a ring carbon atom.

10

11. An imaging or contrast agent as claimed in any of the preceding claims, wherein said compound has a single chiral carbon and said stereoisomer in stereoisomeric excess is in the R form.

12. An imaging or contrast agent as claimed in any of the preceding claims comprising iopamidol, iohexol, ioversol, iodixanol, iomeprol, iopentol, oipromid or itrolan.

13. An imaging or contrast agent as claimed in claim 12 comprising iopamidol.

20

14. An imaging or contrast agent comprising a stereoisomeric excess of R-iopamidol.

Amended claims

1. An imaging or contrast agent comprising iopamidol characterised in that said agent comprises greater than 50 % of R-iopamidol.
2. The imaging or contrast agent as claimed in claim 1, wherein said agent comprises greater than 80 % R-iopamidol.
3. A use of R-iopamidol in an imaging or contrast agent wherein said agent causes fewer adverse side effects on administration.
4. A use of R-iopamidol to produce an imaging or contrast agent being less chemotoxic.